Vertex Gross Profit from 2010 to 2025

VRTX Stock

USD 503.20 6.98 1.37%

Vertex Pharmaceuticals Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Vertex Pharmaceuticals makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

1990-03-31

Previous Quarter

2.4 B

Current Value

2.5 B

Quarterly Volatility

669.9 M

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 11.6 B, Gross Profit of 10 B or Other Operating Expenses of 11.8 B, as well as many indicators such as Price To Sales Ratio of 8.94, Dividend Yield of 0.0 or PTB Ratio of 7.39. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Vertex Pharmaceuticals over the last few years. Gross profit is a required income statement account that reflects total revenue of Vertex Pharmaceuticals minus its cost of goods sold. It is profit before Vertex Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Vertex Pharmaceuticals' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 6.02 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Vertex Gross Profit Regression Statistics

	Arithmetic Mean	3,943,533,250
	Geometric Mean	1,818,224,132
	Coefficient Of Variation	88.66
	Mean Deviation	3,048,682,938
	Median	2,638,058,000
	Standard Deviation	3,496,348,873
	Sample Variance	12224455.4T
	Range	10B
	R-Value	0.94
	Mean Square Error	1493793.3T
	R-Squared	0.89
	Slope	691,234,456
	Total Sum of Squares	183366831.7T

Vertex Gross Profit History

	2025	10 B
	2024	9.5 B
	2023	8.6 B
	2022	7.9 B
	2021	6.7 B
	2020	5.5 B
	2019	3.6 B

Other Fundumenentals of Vertex Pharmaceuticals

Gross Profit Margin

Vertex Pharmaceuticals Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Net Receivables	Common Stock	Long Term Debt	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.75	0.95	0.98	0.95	-0.02	0.98	0.99	0.4	0.04	0.65	0.93	0.23	0.83	0.55	0.99	0.03	0.66	-0.56	0.78	0.79	0.96	0.89	0.7
Total Stockholder Equity	1.0		-0.78	0.96	0.97	0.96	-0.04	0.97	0.99	0.38	0.02	0.62	0.92	0.24	0.84	0.55	0.99	0.0	0.67	-0.58	0.78	0.76	0.97	0.91	0.67
Net Debt	-0.75	-0.78		-0.72	-0.65	-0.92	0.15	-0.65	-0.79	-0.36	-0.02	-0.09	-0.66	-0.28	-0.72	-0.44	-0.76	0.2	-0.57	0.52	-0.66	-0.21	-0.84	-0.96	-0.13
Retained Earnings	0.95	0.96	-0.72		0.91	0.9	-0.02	0.94	0.95	0.13	-0.12	0.59	0.81	0.14	0.76	0.67	0.94	-0.11	0.46	-0.38	0.64	0.79	0.94	0.87	0.69
Total Liab	0.98	0.97	-0.65	0.91		0.9	0.04	0.99	0.97	0.44	0.1	0.73	0.94	0.2	0.79	0.53	0.97	0.13	0.65	-0.53	0.76	0.85	0.91	0.81	0.78
Total Current Assets	0.95	0.96	-0.92	0.9	0.9		-0.08	0.89	0.96	0.43	0.06	0.44	0.87	0.26	0.83	0.53	0.95	-0.04	0.66	-0.59	0.77	0.57	0.96	0.98	0.47
Short Term Debt	-0.02	-0.04	0.15	-0.02	0.04	-0.08		0.07	-0.02	0.04	-0.13	-0.07	0.01	-0.14	-0.25	0.15	-0.06	-0.05	-0.18	0.21	-0.14	0.14	-0.05	-0.1	0.05
Accounts Payable	0.98	0.97	-0.65	0.94	0.99	0.89	0.07		0.96	0.38	0.09	0.71	0.92	0.2	0.72	0.57	0.96	0.13	0.57	-0.47	0.69	0.86	0.91	0.82	0.77
Net Receivables	0.99	0.99	-0.79	0.95	0.97	0.96	-0.02	0.96		0.39	0.02	0.6	0.92	0.24	0.86	0.55	0.99	-0.01	0.67	-0.56	0.8	0.74	0.96	0.91	0.67
Common Stock	0.4	0.38	-0.36	0.13	0.44	0.43	0.04	0.38	0.39		0.6	0.35	0.57	0.3	0.37	-0.04	0.39	0.4	0.73	-0.62	0.5	0.16	0.4	0.33	0.23
Long Term Debt	0.04	0.02	-0.02	-0.12	0.1	0.06	-0.13	0.09	0.02	0.6		0.16	0.21	-0.03	0.02	-0.09	0.02	0.87	0.31	-0.23	0.01	-0.03	0.08	0.01	0.05
Short Term Investments	0.65	0.62	-0.09	0.59	0.73	0.44	-0.07	0.71	0.6	0.35	0.16		0.66	0.01	0.5	0.28	0.63	0.32	0.35	-0.34	0.39	0.84	0.51	0.31	0.78
Property Plant Equipment	0.93	0.92	-0.66	0.81	0.94	0.87	0.01	0.92	0.92	0.57	0.21	0.66		0.23	0.74	0.28	0.94	0.24	0.78	-0.75	0.79	0.74	0.86	0.79	0.68
Current Deferred Revenue	0.23	0.24	-0.28	0.14	0.2	0.26	-0.14	0.2	0.24	0.3	-0.03	0.01	0.23		0.09	-0.14	0.28	-0.14	0.45	-0.35	0.56	0.07	0.24	0.2	0.08
Good Will	0.83	0.84	-0.72	0.76	0.79	0.83	-0.25	0.72	0.86	0.37	0.02	0.5	0.74	0.09		0.45	0.84	-0.09	0.7	-0.57	0.77	0.5	0.81	0.79	0.49
Intangible Assets	0.55	0.55	-0.44	0.67	0.53	0.53	0.15	0.57	0.55	-0.04	-0.09	0.28	0.28	-0.14	0.45		0.49	-0.24	0.02	0.29	0.16	0.47	0.63	0.55	0.45
Net Tangible Assets	0.99	0.99	-0.76	0.94	0.97	0.95	-0.06	0.96	0.99	0.39	0.02	0.63	0.94	0.28	0.84	0.49		0.01	0.69	-0.61	0.81	0.76	0.95	0.89	0.7
Long Term Debt Total	0.03	0.0	0.2	-0.11	0.13	-0.04	-0.05	0.13	-0.01	0.4	0.87	0.32	0.24	-0.14	-0.09	-0.24	0.01		0.16	-0.2	-0.07	0.16	-0.06	-0.11	0.16
Capital Surpluse	0.66	0.67	-0.57	0.46	0.65	0.66	-0.18	0.57	0.67	0.73	0.31	0.35	0.78	0.45	0.7	0.02	0.69	0.16		-0.86	0.89	0.39	0.66	0.57	0.46
Deferred Long Term Liab	-0.56	-0.58	0.52	-0.38	-0.53	-0.59	0.21	-0.47	-0.56	-0.62	-0.23	-0.34	-0.75	-0.35	-0.57	0.29	-0.61	-0.2	-0.86		-0.74	-0.3	-0.53	-0.51	-0.29
Short Long Term Debt	0.78	0.78	-0.66	0.64	0.76	0.77	-0.14	0.69	0.8	0.5	0.01	0.39	0.79	0.56	0.77	0.16	0.81	-0.07	0.89	-0.74		0.5	0.73	0.68	0.48
Long Term Investments	0.79	0.76	-0.21	0.79	0.85	0.57	0.14	0.86	0.74	0.16	-0.03	0.84	0.74	0.07	0.5	0.47	0.76	0.16	0.39	-0.3	0.5		0.66	0.45	0.92
Net Invested Capital	0.96	0.97	-0.84	0.94	0.91	0.96	-0.05	0.91	0.96	0.4	0.08	0.51	0.86	0.24	0.81	0.63	0.95	-0.06	0.66	-0.53	0.73	0.66		0.93	0.61
Net Working Capital	0.89	0.91	-0.96	0.87	0.81	0.98	-0.1	0.82	0.91	0.33	0.01	0.31	0.79	0.2	0.79	0.55	0.89	-0.11	0.57	-0.51	0.68	0.45	0.93		0.35
Capital Stock	0.7	0.67	-0.13	0.69	0.78	0.47	0.05	0.77	0.67	0.23	0.05	0.78	0.68	0.08	0.49	0.45	0.7	0.16	0.46	-0.29	0.48	0.92	0.61	0.35

Click cells to compare fundamentals

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	9.5 B	10 B
Gross Profit Margin	0.86	1.09

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC